Thar Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Thar Pharmaceuticals, Inc.
L’Occitaine’s $900m Elemis buy will build out the manufacturer/retailer’s premium, natural-oriented beauty portfolio, adding a prestige brand that aspires to be a leader in global skin care with its nature/science balance and cross-generational consumer appeal.
Keeping Track: Approvals For Pfizer's Eucrisa, Vericel's Maci; Submissions From Flexion, AcelRx, Ironshore
The latest drug development news and highlights from our FDA Performance Tracker.
Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.
With later-stage in-licensing assets becoming harder to find, Merck is seeking to work more often and in varied ways with academic and institutional researchers to advance its pipeline. Recent tech transfer deals include Cancer Research UK’s transactions with ProNAi and Artios.